logo

For the Inventor, By the Inventor

Middletown, NJ, United States of America

Edward F Rogers

USPTO Granted Patents = 15

Average Co-Inventor Count = 2.7

ph-index = 3

Forward Citations = 37(Granted Patents)


Company Filing History:

goldMedal15 out of 4,770 
 
Merck + Co., Inc.
 patents

Years Active: 1976-1992

Loading Chart...
15 patents (USPTO):Explore Patents
1. 5147868 - Thienamycin renal peptidase inhibitors (1992-09-15),
2. 4739113 - Bis(cyclopropanecarboxamido)alkadienedioic acids as renal dipeptidase (1988-04-19),
3. 4622330 - Antiprotozoal 3-amino or substituted amino pyrazoles (1986-11-11),
4. 4290966 - Process for the preparation of traumatin (1981-09-22),
5. 4173631 - 7-Methyl-8-methylamino-10-(1'-D-ribityl)isoalloxazine (1979-11-06),
6. 4091094 - 9-Azariboflavin and pharmaceutical composition containing same (1978-05-23),
7. 4079069 - 5-Deazariboflavin and its derivatives (1978-03-14),
8. 4053602 - Compositions for treating coccidiosis containing 5-deazariboflavin and (1977-10-11),
9. 4044133 - Anticoccidial compositions (1977-08-23),
10. 4017505 - 1-(N-Octylthiocarbonyl)-2-(4-thiazolyl)benzimidazole (1977-04-12),
11. 4017504 - Antifungal 1-substituted benzimidazoles (1977-04-12),
12. 4017503 - Antifungal 1-substituted benzimidazoles (1977-04-12),
13. 4006143 - Heterocyclic substituted pyrimidine compounds (1977-02-01),
14. 3968228 - 4-Nitro-5-cyanoimidazoles as coccidiostats (1976-07-06),
15. 3957997 - Anticoccidial complexes of 4,4'-dinitrocarbanilides (1976-05-18),

Title: **Innovative Contributions of Edward F. Rogers in Pharmaceutical Chemistry**

Introduction

Edward F. Rogers, based in Middletown, NJ, is a distinguished inventor with an impressive portfolio of 15 patents to his name. His work primarily focuses on novel chemical compounds that play a crucial role in enhancing the effectiveness of antibacterial products through selective inhibition mechanisms.

Latest Patents

Among his latest patents, Edward has developed innovative compounds such as thienamycin renal peptidase inhibitors. These compounds are engineered to selectively inhibit the metabolism of dipeptidase (E.C.3.4.13.11), showing potential in combination with various antibacterial therapies. Additionally, he has created bis(cyclopropanecarboxamido)alkadienedioic acids that serve a similar purpose by selectively inhibiting renal dipeptidase, contributing significantly to the advancement of pharmaceutical chemistry.

Career Highlights

Edward F. Rogers is currently affiliated with Merck & Company, Inc., where he applies his expertise in drug development and innovative chemistry. His continued dedication to research has led to significant advancements within the company and the broader medical community.

Collaborations

Throughout his career, Edward has collaborated with notable professionals including Donald W. Graham and Wallace T. Ashton. These collaborations have fostered a dynamic exchange of ideas, pushing the boundaries of what's possible in the field of pharmaceutical innovation.

Conclusion

Edward F. Rogers stands out as a significant contributor to pharmaceutical science. His innovative inventions, particularly in renal peptidase inhibitors, reflect a commitment to improving therapeutic options for infections. With a proven track record of collaboration and innovation at Merck & Company, Inc., Edward's work continues to have a lasting impact on the industry.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…